)
Gossamer Bio (GOSS) investor relations material
Gossamer Bio Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Special Meeting called to approve share issuances related to a private placement and to allow adjournment if needed.
Private placement involves pre-funded warrants and preferred stock convertible to common stock, contingent on stockholder approval.
Reverse stock split (1-for-80) was effected on September 10, 2026, impacting all share calculations.
Board unanimously recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1 seeks approval for issuance of common stock upon exercise/conversion of warrants and preferred stock, exceeding 20% of pre-transaction shares.
Proposal 2 allows adjournment of the meeting to solicit more proxies if necessary.
Only stockholders of record as of September 14, 2026, are eligible to vote.
Stockholder proposals for the 2027 annual meeting must be received by December 25, 2026, for inclusion.
Board of directors and corporate governance
Board includes recent appointee Gregory A. Ciongoli, who is also a purchaser in the private placement.
Board members and certain executives are participating in the private placement through controlled entities.
Board recommends voting “FOR” both proposals.
- Seralutinib advances toward FDA submission with strong clinical backing and broad label expectations.GOSS
12th Annual Cantor Fitzgerald Global Healthcare Conference - Seralutinib demonstrated strong efficacy and safety in PAH, with NDA submission targeted for Sept. 2026.GOSS
Corporate presentation - Approval sought for major share issuance tied to private placement and FDA milestones.GOSS
Proxy filing - Q2 2026 net income achieved via debt restructuring; NDA submission and liquidity risks remain.GOSS
Q2 2026 - NDA for seralutinib in PAH on track for September 2026, with global rights and reduced debt.GOSS
Investor update - Seralutinib advances toward late-stage data with strong safety, efficacy, and market potential.GOSS
Barclays 27th Annual Global Healthcare Conference 2025 - Seralutinib improved 6MWD and biomarkers in high-risk PAH, despite missing the primary endpoint.GOSS
Study result - PROSERA phase III nears full enrollment; Q1 net loss narrows, cash runway into 2027.GOSS
Q1 2025 - Seralutinib's phase III trial nears completion, aiming to deliver top-line data by Q4 2024.GOSS
Emerging Growth Conference 79
Next Gossamer Bio earnings date
Next Gossamer Bio earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)